









Markets
/
Stocks
/
nasdaq-auph
/

Aurinia Pharmaceuticals Inc

AUPH

13.975USD

-0.625-4.28%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

48.61MMarket Cap

6.54P/E TTM



Aurinia Pharmaceuticals Inc

13.975

-0.625-4.28%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aurinia Pharmaceuticals Inc

Currency: USD Updated: 2026-03-27

Key Insights

Aurinia Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 82 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aurinia Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

82 / 391

Overall Ranking

194 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Aurinia Pharmaceuticals Inc Highlights

StrengthsRisks

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 61.27% year-on-year.

Fairly Valued

The company’s latest PE is 6.68, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 66.87M shares, increasing 0.10% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 127.39K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.56.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

17.000

Target Price

+16.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Aurinia Pharmaceuticals Inc is 8.76, ranking 26 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 77.11M, representing a year-over-year increase of 28.81%, while its net profit experienced a year-over-year increase of 14651.15%.

Score

Industry at a Glance

Previous score

8.76

Change



Financials

8.75

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.36

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.69

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Aurinia Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Aurinia Pharmaceuticals Inc is 5.10, ranking 380 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 6.68, which is 3245.13% below the recent high of 223.33 and 1095.39% above the recent low of -66.45.

Score

Industry at a Glance

Previous score

5.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 82/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Aurinia Pharmaceuticals Inc is 7.43, ranking 296 out of 391 in the Biotechnology & Medical Research industry. The average price target is 17.00, with a high of 21.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

7.43

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

17.000

Target Price

+19.13%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Aurinia Pharmaceuticals Inc

AUPH

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Aurinia Pharmaceuticals Inc is 6.43, ranking 225 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 15.06 and the support level at 13.66, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.09

Change

-0.66

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.045

Neutral

RSI(14)

47.947

Neutral

STOCH(KDJ)(9,3,3)

37.899

Neutral

ATR(14)

0.535

High Vlolatility

CCI(14)

-17.578

Neutral

Williams %R

69.091

Sell

TRIX(12,20)

-0.064

Sell

StochRSI(14)

14.908

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

14.402

Sell

MA10

14.296

Sell

MA20

14.386

Sell

MA50

14.494

Sell

MA100

15.003

Sell

MA200

12.875

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Aurinia Pharmaceuticals Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 49.23%, representing a quarter-over-quarter decrease of 2.60%. The largest institutional shareholder is James Simons, holding a total of 1.59M shares, representing 1.20% of shares outstanding, with 72.15% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Tang Capital Management, LLC

11.33M

+12.96%

BlackRock Institutional Trust Company, N.A.

6.22M

-3.73%

ILJIN SNT Co., Ltd.

6.54M

-13.10%

New Enterprise Associates (NEA)

3.97M

Arrowstreet Capital, Limited Partnership

3.37M

+213.54%

Two Sigma Investments, LP

1.83M

+417.21%

State Street Investment Management (US)

2.69M

-3.63%

Renaissance Technologies LLC

Star Investors

1.45M

+25.20%

Marshall Wace LLP

1.48M

+1272.51%

D. E. Shaw & Co., L.P.

909.92K

+166.42%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Aurinia Pharmaceuticals Inc is 7.19, ranking 16 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.55. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.